Cannabidiol , synthetic form (DrugBank: Cannabidiol)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 96 | Crohn disease | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04056442 (ClinicalTrials.gov) | July 7, 2019 | 13/8/2019 | A Phase 2a Study to Evaluate the Safety, Tolerability and Efficacy of Cannabidiol as a Steroid-sparing Therapy in Steroid-dependent Crohn's Disease Patients | A Phase 2a, Randomized, Double-blind, Placebo-controlled, Crossover, Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of Cannabidiol (CBD) as a Steroid-sparing Therapy in Steroid-dependent Crohn's Disease Patients | Steroid Dependent Crohn's Disease | Drug: Cannabidiol , synthetic form;Drug: Placebo | Stero Biotechs Ltd. | NULL | Recruiting | 18 Years | N/A | All | 28 | Phase 2 | Israel |